We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Loss of STAG2 Gene Improves Bladder Cancer Prognosis

By LabMedica International staff writers
Posted on 23 Oct 2013
Results obtained during a study conducted by Spanish cancer researchers indicated that mutations of the STAG2 (stromal antigen 2) gene suppressed development of urothelial bladder cancer (UBC) by acting through mechanisms that were different from the gene's role in preventing aneuploidy.

The protein encoded by the STAG2 gene is a subunit of the cohesin complex, which regulates the separation of sister chromatids during cell division. More...
Targeted inactivation of this gene results in chromatid cohesion defects and aneuploidy, suggesting that genetic disruption of cohesin is a cause of aneuploidy in human cancer.

Bladder cancer represents a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded every year, one of the highest rates in the world. The majority of these tumors have a good prognosis for five-year survival after diagnosis, and most have not infiltrated the bladder muscle at the time of diagnosis.

Investigators at the Spanish National Cancer Research Center (Madrid) performed an exome sequencing study to identify genes linked to noninfiltrating bladder cancer. They analyzed the exome from 17 bladder cancer patients and subsequently validated the data by the analyzing a specific group of genes in 60 additional patients.

Results published in the October 13, 2013, online edition of the journal Nature Genetics revealed a set of previously unidentified genes mutated in these tumors coding for proteins involved in chromatin modification (MLL2, ASXL2, and BPTF), cell division (STAG2, SMC1A, and SMC1B) and DNA repair (ATM, ERCC2, and FANCA). STAG2 was significantly and commonly mutated or lost in UBC, mainly in tumors of low stage or grade, and its loss was associated with improved outcome.

Loss of STAG2 expression was often observed in chromosomally stable tumors, and STAG2 knockdown in bladder cancer cells did not increase aneuploidy. Insertion of STAG2 into nonexpressing cells led to reduced colony formation. Furthermore, analysis of bladder tumor tissue from more than 670 patients indicated that alterations in STAG2 were associated with a better prognosis.

"We found up to nine altered genes that had not been described before in this type of tumor, and of these we found that STAG2 was inactive in almost 40% of the least aggressive tumors," said senior author Dr. Francisco X. Real, head of the epithelial carcinogenesis group at the Spanish National Cancer Research Centre. "Some of these genes are involved in previously undescribed genetic pathways in bladder cancer, such as cell division and DNA repair; also, we confirmed and extended other genetic pathways that had previously been described in this cancer type, such as chromatin remodeling."

Related Links:

Spanish National Cancer Research Center



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.